Rossari Biotech Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/elq59cmncocajv2zklmkjnst.pdf

Key Takeaways


Core Operations vs. Consumer Drag

Ketan Sablok: "We will be holding on to the margin this year. I thought we will drive some operating leverage, right? The employee cost is largely done, and we are cutting losses in the institutional."

Production Disruption & Export Miss


Capacity Expansion & the EO Timeline

Sunil Chari: "The Reliance expansion is delayed, and it may take a few more quarters for them to start delivering higher EO. But considering the softness in all India consumption of EO, we are able to get more EO than we were getting normally."

Non-EO Diversification & Overseas Foray

Sunil Chari: "The competition is all the global majors, who are the big global majors like Dow, BASF, Lubrizol, INEOS, Nouryon, Sasol, Stepan. So, these are the big ones who are global majors everywhere in the world."

Margin & Cost Structure

Ketan Sablok: "Yes, it should grow, but we are still being a little cautious because pricing is still a challenge for us. Some of the raw material prices have come down, and we expect that some of that we will have to give up in the coming quarters."

Guidance & Commitments

CommitmentSpecificsTimeline
Lost export fulfillmentMissed Q1 export orders to be dispatchedQ2 FY26
Annual revenue & EBITDA growthMid-double-digit, 14-15% growth on both top line and EBITDAFY26 (annual)
B2C/institutional breakevenLosses to reduce substantially; possible breakeven if next 2 quarters go well; definite breakeven by next yearBy FY27 at EBITDA level
Capacity-driven margin expansion3x-4x asset turnover from new facilities, driving operating leverage and margin expansionFrom FY27 onwards
Reliance enhanced EO availabilityReliance capacity expected on streamSep-Oct 2026 (per Reliance indication)
Optimal capacity utilizationGood utilization of expanded capacityFY28, with 3-4 years to 100%
Overseas facility CAPEXInitial ₹15-20 crore; further expansion contingent on market acceptanceStarting now; expansion timeline uncommitted

Key Metrics

MetricQ1 FY26
Revenue from operations₹543.7 crore, up 11.0% YoY
Volume growth11% YoY
EBITDA₹67.9 crore, up 4.6% YoY
EBITDA margin12.5%, compared to 13.3% in Q1 FY25
EBITDA (excl. institutional and B2C)₹75 crore, up 12% YoY, adjusted margin about 16%
Institutional and B2C business loss~₹7 crore in Q1
Institutional and B2C business FY25 revenue₹299 crore
Exports₹139 crore in Q1, expected 27%-28% of overall turnover on annualized basis
Core business QoQ revenue changeDown by ₹25 – ₹30 crore compared to Q4 FY25
Production stoppage10-12 days intermittently due to CAPEX-related hot work
Expected annual revenue and EBITDA growth14%-15% (mid-double-digit)
Overseas formulation facility CAPEX₹15 crore – ₹20 crore
Institutional business gross margins28% to 30%
Other expenses YoY increase~₹12 crore, ~50% from Institutional Business